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IntRoductIon
Hepatitis B is the most important occupational infectious disease. Transmission of hepatitis B from patients to healthcare workers (HCWs) and from HCWs to patients has been described. [1] According to the WHO, 5.9% of HCWs are each year exposed to blood-borne HBV infections corresponding to about 66,000 HBV infections in HCWs worldwide. [2] Hepatitis B virus (HBV) infection can be prevented through HBV surface antigen (HBsAg) vaccination. Vaccine efficacy studies have demonstrated protection against acute and chronic disease in immunocompetent vaccine responders. [3] The schedules for vaccination approved by most regulatory authorities which are as follows: [4] 0,1 and 6 months (first dose followed by a dose 1 month and 6 months after the first) and 0, 1, 2 and 12 months (first dose followed by a dose 1 month, 2 months and 12 months after the first). The '0, 1, 2 and 12 months' schedule should be considered when rapid protection is required in high-risk groups such as HCWs. Protective antibody titres are achieved in almost all recipients by 3 months. To ensure an enduring high antibody titre following rapid vaccination, a fourth dose must be given at 12 months. For routine immunisation, the '0, 1 and 6 months' schedule is less costly and provides excellent antibody titres and duration of protection.
Testing for evidence of protective immunity to HBsAg vaccination is essential, as some vaccinated HCWs do not develop sufficient levels of antibodies against HBsAg (anti-HBs). [5] An anti-HBs level of >10 mIU/ml, is considered as protective against HBV infection.
[6] An anti-HBs titre of <10 mIU/ml is regarded as non-responsiveness to HBsAg vaccination. [7] Anti-HBs levels between 10 and 100 mIU/ml are regarded as hyporesponsiveness, and levels >100 mIU/ml are taken as a high level of immunity.
Smoking, obesity, aging, chronic medical conditions, male sex, genetic factors and immunosuppression are associated with a decrease in immune response. [8, 9] The current study is aimed to evaluate immune response to HbsAg vaccination in HCWs and the factors associated with decreased immune response.
methods
This was a cross-sectional study conducted from April 2013 to 2014 in a tertiary care hospital after obtaining the Institutional Ethical Clearance. All HCWs, who have received the complete standard course of intramuscular HBsAg vaccination, were included in the study population. Known HBsAg positive HCWs, were excluded from the study.
With 99% confidence level and absolute allowable error of 5%, the minimum sample size required is 77. Hence, 85 sample sizes were taken. The study population consisted of 85 HCWs. The anti-HBs level was measured in the collected serum samples using a commercially available ELISA (New Medical Biological Service, S. R. L., Opera, Milano, Italy). Data were analysed categorically for gender, age, time elapsed since the last dose of vaccination, smoking habit and body mass index (BMI) against anti-HBs levels using SPSS 20 software. Comparisons were made using cross tabulation with the Chi-square test, and P < 0.05 was considered statistically significant.
Results
The study population comprised 45 (52.95%) females and 40 (47.05%) males. Of the total 258 participants, 85 (32.9%) had received all three or five doses of vaccination and the rest had received two doses only. 21 (24.7%) participants had taken booster doses in addition.
Overall, 96.5% of the vaccinated HCWs developed protective immunsity to hepatitis B. Of these 20.0% had an anti-HBs titre between 10 and 100 mIU/ml and the rest (76.5%) had an anti-HBs titre of >100 mIU/ml. 3.5% of the vaccinated HCWs did not develop a sufficient anti-HBs response [ Table 1 ]. The anti-HBs response was similar in both male and female (P = 0.70) [ Table 1 ]. There was a decline in immune response as the age was increasing.(P = 0.007) [ Table 1 ]. The time elapsed between the last dose of vaccination and the time of assessment of anti-HBs levels ranged from 6 months to 19 years. It was evident that immunity against HBV had reduced significantly overtime (P = 0.004) [ Table 1 ]. The anti-HBs response was declined with smoking habit (P = 0.004) and with increasing BMI (P = 0.00004) [ Table 1 ]. The anti-HBs response was not affected by the vaccination schedule (0, 1 and 6 schedule or 0, 1, 2 and 12 months' schedule) and number of booster doses [ Table 1 ].
dIscussIon
The age range of the study participants was 20-55 years, with mean and standard deviation being 31.17 and 7.12, respectively, in male and 29.04 and 9.36 in female. The mean BMI was 22.65, and the standard deviation was 1.71 in male. In the female, the mean and standard deviation of BMI were 21.42 and 2.42, respectively.
In this study, 96.5% have protective immunity to hepatitis B suggesting our results are compatible with Varshochi et al. [6] and Thomas et al. [10] who showed 98.54% and 98.89% protective immunity, respectively. Chakrabarthy et al., [11] Chathuranga et al. [12] and Nagamani et al. [13] showed 100%, 91.1% and 100% protective immunity, respectively.
No association between gender and the rate of seroconversion to anti-HBs was found in the current study as in some studies. [14] Some authors have found a poor response in males than in females. The effect of gender could be explained by the greater weight of men; [15] however, others have shown that males have a lower response rate even after correcting the weight. In this study, as there was no much difference in mean BMI of male and female probably the immune response was not affected.
Poor anti-HBs response was seen as the age was increased from as low as 35 years in our study concurrence with previous studies.
[ 16] Theoretically, this age effect could be due to a decrease in lymphocyte proliferation activity.
The time elapsed between the last dose of vaccination and the time of assessment of anti-HBs levels ranged from 6 months to 19 years. The mean months after the last dose of vaccination were 60.36. Our findings show that the anti-HBs level significantly declines with time as in previous studies. [17] Although antibody titre declines with time, it should be reasonable to the level of 10 mIU/ml at any time for ensuring immunoprotection among vaccinated individuals. [18] Smoking is strongly associated with a poor response rate to hepatitis B vaccine as shown by this study and others. [6, 19] The probable reason could be lower immunoglobulins in smokers than in nonsmokers. [20] Smoking is known to impair dendritic cell function. [21] With increased BMI from >25, the immune response was decreased in the current study. In some studies, a significant association was found, [8] and in some no significant association was found [6, 14] between BMI and the immune response.
The limitation of our study was inability to study genetic factors. Another limitation was immunocompromised vaccinated HCWs not there in our study participants; hence, we could not evaluate protective immunity in them.
The findings of our study provide a base for testing for anti-HBs in hepatitis B vaccinated HCWs in India as very few studies were there in India. Although the current vaccines are highly effective, the protective immune response rate is substantial in elderly, smokers, obese individuals and those with chronic hepatic or chronic renal diseases. A lot of research is still needed in developing newer vaccines from ongoing works such as incorporating HBV DNA sequences coding for pre-S1 and pre-S2 protein in hepatitis B vaccine and improvement of the adjuvants to make the vaccine more immunogenic. [22] The poor response to hepatitis B vaccine can be improved by a different route of vaccine administration, increased dose and frequency of vaccination. Other approaches include hepatitis B DNA vaccination with plasmid DNA encoding HBsAg [23] or administration of HBsAg-pulsed blood dendritic cells. More studies are needed to confirm these findings.
conclusIon
Protective immune response to hepatitis B vaccine among HCWs is 96.5%. Increasing age, increasing duration since vaccination, smoking habit and overweight are associated with decreased protective immune response to hepatitis B. Many studies are needed in developing newer HBV vaccines with very high immunogenicity. Giving highly immunogenic vaccine to HCWs will ensure safety at work by reducing nosocomial transmission which is very much desired in a resource-limited country.
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